NCT02691078已完成2 期
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Analysis of the images captured with 99m Tc - HYNIC -TOC EDDA ( octreotide labeled with 99mTc ) and 111In - DTPA-octreotide for the diagnosis of neurocrine tumors
研究概览
简要总结
Evaluation of the properties of the image capture test using 99m Tc - HYNIC -TOC EDDA (octreotide labeled with 99mTc) for the diagnosis of neuroendocrine tumors compared to the 111In - DTPA-octreotide.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histological diagnosis of neuroendocrine tumors
- •Patients with indication for the staging exam with 11In
- •Patients diagnosed in any tumor stage
- •Patients with > 18 years
- •Male and female patients
- •Patients not receiving somatostatin analogues for at least 1 month before image capturing
排除标准
- •Pregnant women
- •Patients with previous tumor resection of the primary tumor without metastatic disease
研究组 & 干预措施
Adult patients with neuroendocrine tumors
Experimental
干预措施: 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide (Other)
结局指标
主要结局
Analysis of the images captured with 99m Tc - HYNIC -TOC EDDA ( octreotide labeled with 99mTc ) and 111In - DTPA-octreotide for the diagnosis of neurocrine tumors
时间窗: Up to 30 days
次要结局
- Visualization of the ocurrence of the neuroendocrine tumor lesions with both radiopharmaceutical agents(Up to 30 days)
- Number of neuroendocrine tumor lesions visualized with both radiopharmaceutical agents(Up to 30 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study of FolateScan in Patients With Knee OsteoarthritisKnee OsteoarthritisNCT01237405Virginia Kraus25
撤回
不适用
OCT Image Quality Performance EvaluationHealthy EyesNCT02991027Topcon Medical Systems, Inc.
终止
3 期
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RARheumatoid ArthritisNCT05246280Navidea Biopharmaceuticals169
已完成
不适用
Application of IV 99mTc-tilmanocept for Imaging of Macrophage-specific InflammationHIVNCT03523130Massachusetts General Hospital9
招募中
1 期
Evaluation of CCR2 in Patients Post Myocardial InfarctionHeart DiseasesNCT05107596Washington University School of Medicine90